(Q44189645)

English

Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.

scientific article published on 29 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

cell traversal protein for ookinetes and sporozoites

1 reference

11 September 2018

0 references

cell traversal protein for ookinetes and sporozoites

1 reference

19 December 2018

cell traversal protein for ookinetes and sporozoites

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

Christian F Ockenhouse

4

object named as

Christian F Ockenhouse

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

5

object named as

Evelina Angov

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Elke S Bergmann-Leitner

1

object named as

Elke S Bergmann-Leitner

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Tatyana Savranskaya

3

object named as

Tatyana Savranskaya

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Patricia M Legler

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

29 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

5940-5949

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Plasmodium falciparum malaria vaccines in development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Specificity of Protective Immunity produced by X-irradiated Plasmodium berghei Sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Improved technique for the preparation of water-in-oil emulsions containing protein antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Simple Centrifugation Method for Rapid Separation of Sporozoites from Mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Thermally induced structural changes of intrinsically disordered small heat shock protein Hsp22

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

MFG-E8/Lactadherin Promotes Tumor Growth in an Angiogenesis-Dependent Transgenic Mouse Model of Multistage Carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improvesprotection against malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Progress and prospects: the design and production of plasmid vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Optimization and delivery of plasmid DNA for vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.053

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.06.053

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44189645&oldid=2108369507"